openPR Logo
Press release

What's driving the Angina Pectoris Treatment Market Growth? Prominent Players: Abbott., AstraZeneca, Bayer AG, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Allergan and more

10-22-2019 09:01 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Fortune Business Insights

What's driving the Angina Pectoris Treatment Market Growth?

The global angina pectoris treatment market is anticipated to gain impetus from the increasing awareness programs regarding the availability of several therapy options. Fortune Business Insights, in an upcoming report, titled, “Angina Pectoris Treatment Market Size, Share and Global Trend By Drug Class (Beta Blockers, Calcium Antagonists, Anti-coagulants, Anti-Platelets), Disease Type (Stable or chronic angina, Unstable angina, Variant and microvascular angina), Distribution Channel (Online pharmacies, Hospital pharmacies, Retail pharmacies) and Geography Forecast till 2026,” rising per capita healthcare spending, availability of personalized medicine, and surge in the economies are expected to boost the global angina pectoris treatment market growth in the coming years. Moreover, a rising number of upcoming pipelines for potential candidates will also contribute to growth.

Browse Complete Report Details at

Top Leaders Overview:

Some of the leading companies in the global Angina Pectoris Treatment Market are
• Abbott.
• AstraZeneca
• Bayer AG
• Bristol-Myers Squibb
• F. Hoffmann-La Roche Ltd
• Allergan
• Gilead Sciences
• GlaxoSmithKline Pharma GmbH
• Novartis
• Pfizer
• Sanofi and other key players.

The report offers global angina pectoris treatment market share assessment for the country as well as regional level segments. It further provides strategic recommendations for the new entrants in the market. Furthermore, the report aids in providing supply chain trends by mapping the ongoing technological advancements.

By Drug Class
• Beta-Blockers
• Calcium Antagonists
• Anti-coagulant
• Anti-Platelets
• Nitrates
By Disease Type
• Stable or chronic angina
• Unstable angina
• Variant and microvascular angina
By Distribution Channel
• Online pharmacies
• Hospital pharmacies
• Retail pharmacies

New Innovative Product Launches to Favor Growth in North America

The global angina pectoris treatment market is geographically divided into Latin America, Asia Pacific, Europe, the Middle East and Africa, and North America. Out of these, North America is projected to lead the global market during the forecast period. It would occur due to the introduction of several guidelines involved in managing and diagnosing patients suffering from stable ischemic heart disease.

Get Sample PDF Brochure at

New product launches also contribute to the growth in this region. Asia Pacific, on the other hand, is considered to remain in the second-fastest-growing market due to the rising economies in the healthcare sector.

Janssen Receives FDA Approval for its Rivaroxaban (Xarelto) to Expand its Usage
In October 2018, the FDA officials declared its approval for Janssen’s rivaroxaban (Xarelto). The oral anticoagulant was first approved in 2011. It is now meant to reduce the risk of acute cardiovascular (CV) events, namely, stroke, myocardial infarction (MI), and death in those with chronic peripheral or coronary artery disease (PAD/CAD). FDA approval makes rivaroxaban the only Factor Xa inhibitor that is for the patients suffering from these conditions. Janssen is a renowned pharmaceutical company based in Belgium.

In spite of the usage of guideline-recommended therapies, sufferers of chronic PAD or CAD are at high risk of having an irreversible and devastating CV event. The latest Xarelto vascular 2.5mg dose is to bed used with aspirin. It represents a breakthrough for patients with chronic PAD and CAD.

AstraZeneca Enters into Strategic Collaboration with Recordati to Deliver Seloken in Europe
AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, headquartered in the U.K., announced that it has partnered up with Recordati, an Italy-based pharmaceutical company in May 2017. The main of the collaboration is to gain commercial rights to Seloken ZOK (metoprolol succinate) and associated Logimax fixed-dose combination treatments in Europe. Metoprolol succinate aids in controlling heart failure, angina, and hypertension. AstraZeneca received a payment of USD 300 from Recordati after the completion of this partnership. AstraZeneca will develop and supply the medicines to the latter under another supply agreement. Product sales for Logimax and Seloken brands were USD 100 million in Europe, in 2016. AstraZeneca will commercialize these medicines in all the markets where it holds the rights.

Speak To Analyst at

Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release What's driving the Angina Pectoris Treatment Market Growth? Prominent Players: Abbott., AstraZeneca, Bayer AG, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Allergan and more here

News-ID: 1854107 • Views: 52

More Releases from Fortune Business Insights

What's driving the Intracranial Stents Growth? Prominent Players: Acandis GmbH, …
According to a report by Fortune Business Insights, titled “Intracranial Stents Market Size, Share and Global Trend by Product (Self-Expanding Intracranial Stents, Embolization Coil Support Intracranial Stents), By Disease Indication (Brain Aneurysm, Intracranial Stenosis), By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others), and Geography Forecast till 2026,” the market derives growth from increasing regulatory approvals for related products. Browse Complete Report Details at Some of the major companies that
Why the Agricultural Spray Surfactants Market is set to explode? Top Companies : …
Aberrant usage of crop protection chemicals has led to the deformation of the environment in recent times says Fortune Business Insights in a report, titled “Agricultural Spray Surfactants Market Size, Share and Global Trend by Type (Anionic, Cationic, Amphoteric, Non-ionic), Application (Insecticides, Fungicides, Herbicides), Formulation (Tank-mix, In-formulation), Substrate/Feedstock (Synthetic, Bio/Plant-based) and Geography Forecast till 2026”. The increasing demand for precision farming is expected to have maximum impact on the agricultural
What's driving the Agricultural Microbial Growth? Prominent Players: Monsanto Co …
The Global Agricultural Microbial Market is prophesied to grow with rising adoption of natural and organic farming worldwide. Fortune Business Insights shared this information in a report, titled “Agricultural Microbial Market Size, Share and Global Trend by Type (Bacteria, Fungi, Virus), Formulation (Dry formulation, Liquid Formulation), Mode of Application (Soil Treatment, Foliar Spray, Seed Treatment), Function (Soil Ammendment, Crop Protection), Crop Type (Cereals, Oilseeds, Fruits & Vegetables) & Geography Forecast
Why the Precision Diagnostics Market is set to explode? Top Companies: Pfizer In …
Developments in The Human Genome Project has given tailwinds to the global precision diagnostics market. Fortune Business Insights announced this information in a report, titled “Precision Diagnostics Market Size, Share and Global Trend By Type (Genetic tests, Esoteric tests), End Users (Hospitals, Clinical laboratories) and Geography Forecast till 2026.” This project has given birth to novel precision medicine, allowing tailored diagnosis as per the patient’s specifications. Browse Complete Report Details

All 5 Releases

More Releases for AstraZeneca

HPAPI 2019 Conference: Exclusive Interview Released with AstraZeneca
Peter Marshall from AstraZeneca will be speaking at SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference which will take place in London on 13th-14th May. He will be discussing the latest developments in the industry with a specific focus on the principles of pharmaceutical containment in isolator design. Ahead of the conference, SMi had interviewed him where he gave a taster of what he will be discussing. Peter said: “The
Global Hospital Infection Therapeutics Market 2019 - AstraZeneca, Pfizer, Merck, …
Hospital-acquired infections, also known as nosocomial infections, are acquired by patients in the hospitals or healthcare facilities. Urinary tract infections, bloodstream infections, surgical-site infections, Clostridium difficile associated diarrhea, and pneumonia are examples of nosocomial infections. Get Free Sample Copy of Report Here: Scope of the Report: This report studies the Hospital Infection Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries;
Global Inflammatory Bowel Disease Market 2019 - Pfizer, AstraZeneca, Cephalon, A …
Apex Market Reports, recently published a detailed market research study focused on the “Inflammatory Bowel Disease Market” across the global, regional and country level. The report provides 360° analysis of “Inflammatory Bowel Disease Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Inflammatory
Gene Editing Market - Gained prominence 2025 | Agilent Technologies, AstraZeneca
Global Gene Editing Market: Snapshot Gene editing or genome editing is the targeted insertion or modification of cells in living organism or cells and the method has come to occupy a crucial part of biomedical researches, constantly transforming various disciplines of life sciences. Over the past few years, continuous advancements in gene-editing technologies have led to the advent of several versatile methods, which have enabled investigators to introduce a number
Cancer Diagnostics Market – Transformation Report 2025 | AstraZeneca, Ambry Ge …
Global Cancer Diagnostics Market: Snapshot With the tremendous rise in the prevalence of cancer across the world, the global market for cancer diagnostics is witnessing a remarkable surge in its size. The technological advancements in devices used in the diagnosis of cancer are also supporting the growth of this market, significantly. One of the main causes of deaths, globally, is cancer. Therefore, medical and healthcare professionals are concentrating on the development
Biotechnology Market Is Booming | Roche, Pfizer, Merck, Sanofi, AstraZeneca
HTF MI recently introduced Global Biotechnology Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Johnson & Johnson, Roche, Pfizer, Merck, Sanofi, AstraZeneca, Gilead, CELGENE CORPORATION, Biogen,